Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases.
The last earnings update was 13 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Oryzon Genomics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Oryzon Genomics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Oryzon Genomics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Oryzon Genomics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Oryzon Genomics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Carlos Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advisory Board. Dr. Buesa serves as a Member of the Board of Directors at Inveready Asset Management, S.G.E.I.C., S.A. In addition, he sits on the board of other biotech companies like Neurotech Pharma and Oncnosis Pharma. He sits on the Board of various biotech companies, including Oncnosis Pharma AIE, NINFAS AIE, Neurotech SL and Geadig-Pharma AIE, among others. He is Chairman of CataloniaBIO, the association of Catalan biotech companies and he is a Board member at ASEBIO. He also sits on the Executive Committee of BioRegió de Catalunya, a regional foundation set up to foster and coordinate biotech research. Dr. Buesa has produced more than thirty papers and patents internationally, was a Member of the cellular signaling research team in the Pharmacy Faculty at the University of Barcelona, held an EU post-doctoral fellowship in the Faculty of Medicine at the University of Ghent in Belgium and later became Senior Investigator with the Flemish Institute of Biotechnology (VIB), also in Belgium. Dr. Buesa received his PhD in Biology from the University of Barcelona (UB). He has pursued various Finance and Negotiation programmes and in 2005, took the executive leadership programme (PADE) offered by the University of Navarra's IESE Business School.
Carlos Manuel's compensation has been consistent with company performance over the past year, both up more than 20%.
Carlos Manuel's remuneration is higher than average for companies of similar size in Spain.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Oryzon Genomics management team is about average.
Carlos Manuel Arjol
First Deputy President & Chief Scientific Officer
COO & CFO of Spain
Investor Relations Director
Chief Business Development Officer
Chief Intellectual Property Officer
Chief Clinical Officer
Chief Medical Officer
Chief of Clinical Operations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Oryzon Genomics board of directors is about average.
What Kind Of Shareholder Owns Most Oryzon Genomics S.A. (BME:ORY) Stock?
Generally speaking, as a company grows, institutions will increase their ownership. … Oryzon Genomics is a smaller company with a market capitalization of €142m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that.
How Should Investors React To Oryzon Genomics S.A.'s (BME:ORY) CEO Pay?
First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Carlos Manuel Arjol's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below €175m
What Type Of Shareholder Owns Oryzon Genomics SA's (BME:ORY)?
The big shareholder groups in Oryzon Genomics SA (BME:ORY) have power over the company. … Oryzon Genomics is a smaller company with a market capitalization of US$115m, so it may still be flying under the radar of many institutional investors. … View our latest analysis for Oryzon Genomics
Was Oryzon Genomics SA's (BME:ORY) Earnings Growth Better Than The Industry's?
After reading Oryzon Genomics SA's (BME:ORY) latest earnings update (31 March 2018), I found it beneficial to look back at how the company has performed in the past and compare this against the most recent numbers. … As a long-term investor I tend to pay attention to earnings trend, rather than a single number at one point in time. … ORY is loss-making, with the most recent trailing twelve-month earnings of -€4.93m (from 31 March 2018), which compared to last year has become
Does Oryzon Genomics SA.'s (BME:ORY) Latest Financial Perfomance Look Strong?
After looking at Oryzon Genomics SA.'s (BME:ORY) latest earnings announcement (31 December 2017), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … See our latest analysis for Oryzon Genomics How ORY fared against its long-term earnings performance and its industry For the purpose of this commentary, I like to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … For Oryzon Genomics, its latest earnings (trailing twelve month) is -€5.20M, which, in comparison to the prior year's figure, has become less negative.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. Its clinical-stage product candidates include ORY-1001, an oncology product, which is in Phase I/IIA clinical trial for treating acute leukemia disease; and ORY-2001, a dual LSD1 and MAO-B inhibitor that is in Phase IIA clinical trial for multiple sclerosis, Alzheimer’s disease, and other neurodegenerative diseases. The company is also developing ORY-3001, a selective LSD1 inhibitor that is in preclinical stage for the treatment of non-oncological diseases; and additional programs in other cancer indications. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.